Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1, OPEN-LABEL, FIRST-IN-HUMAN TRIAL OF INTRAPERITONEA L Lm-LLO-TT AND GEMCITABINE IN PARTICIPANTS WITH UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

NCT07828236 is registered in ClinicalTrials.gov with Loki Therapeutics, Inc. as lead sponsor.

NCT NCT07828236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07828236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1, OPEN-LABEL, FIRST-IN-HUMAN TRIAL OF INTRAPERITONEA L Lm-LLO-TT AND GEMCITABINE IN PARTICIPANTS WITH UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Lead sponsor
Loki Therapeutics, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
January 30, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic adenocarcinoma, pancreas cancer, duct cell adenocarcinoma, pancreatic cancer